Reacting to a Cancer Diagnosis

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

An expert advises a few things to keep in mind when patients with cancer are navigating these platforms.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.